Current Drug Trends for the Treatment of the SARS-CoV-2

(E-pub Ahead of Print)

Author(s): Márcio Robert Mattos da Silva*, Melanie Tavares, Ralph Santos-Oliveira, Eduardo RicciJúnior

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Become EABM
Become Reviewer
Call for Editor


Background: Severe Acute Respiratory Syndrome Coronavirus 2 initially appeared in China and spread rapidly around the world, causing a pandemic. Due to the absence of an effective vaccine, many drugs have been extensively studied for the treatment of the SARS-CoV-2.

Objective: The aim of this work is to provide a current trend of potential drugs for the treatment of SARS-CoV-2 through literature research on drug repositioning.

Method: A literature review was performed on databases such as PubMed, ScienceDirect, Scielo, Lilacs, World Health Organization and Clinical Trials to identify relevant articles of drugs used for the treatment of SARS-CoV-2 from 2003 up to 2020.

Result: Nelfinavir presented favorable results in molecular modeling and in vitro studies. Hydroxychloroquine and Chloroquine showed positive results; nevertheless, the World Health Organization discontinued the clinical trials because these drugs might increase the frequency of ventricular arrhythmia. Darunavir and Ribavirin presented one positive and negative result in molecular modeling and in vitro studies, respectively. The combination of Lopinavir/Ritonavir and Umifenovir alone demonstrated negative results in the clinical trials performed. Remdesivir presented results that were more positive.

Conclusion: The data do not support the use of Lopinavir/Ritonavir and Umifenovir for treatment against SARS-CoV-2. Nelfinavir seems to have the potential to be explored against SARS-CoV-2. Remdesivir showed positive results in several studies against SARS-CoV-2. However, its effectiveness against the virus is under investigation and still not very conclusive.

Keywords: SARS-CoV-2, Antiviral agents, MERS-CoV, SARS-CoV, Coronaviruses, Covid-19

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2666796701999201222114336

Article Metrics

PDF: 1